ArticleBMC gastroenterology2025
Effect of chitosan nanoparticles conjugated with the cell free supernatant of Bifidobacterium bifidum on the expression of genes related to colorectal cancer in colon adenocarcinoma (Caco-2) cell line.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular and Immunological Mechanisms Underlying the Anticancer Effects of Bifidobacterium.Probiotics and antimicrobial proteins · 2026Review
- Integrated Genomic, Structural, and Metabolomic Profiling of Freeze-Dried Postbiotic Supernatants Reveals Multi-Target Anticancer Activity Against Caco-2 Cells.Probiotics and antimicrobial proteins · 2026Article
- There may be a differential mechanistic impact on colorectal cancer of lactose-containing foods between lactase persistent and lactase non-persistent populations.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is emerged as a global problem with high mortality rate; hence, finding of alternative treatment approaches is essential. The purposes of this research are to assess the impact of chitosan nanoparticles conjugated with the cell free supernatant of Bifidobacterium bifidum (CTNP/B.b-sup) on genes associated with CRC signaling pathways.
methodsThe novel nano-drug were fabricated via an ionic gelation technique and analyzed using transmission electron microscopy (TEM) and dynamic light scattering (DLS) methods. The release of protein and entrapment efficiency (EE) of CTNP/B.b-sup were assessed using a BCA protein assay. Following an investigation into the toxicity of CTNP/B.b-sup on Caco-2 cells by MTT assay, the expression of genes associated with CRC signaling pathways was evaluated utilizing real-time PCR method.
resultsCTNP/B.b-sup exhibited a suitable morphology with a particle size of 453.1 ± 230.8 nm and zeta potential of 9.11 ± 3.6 mV. The protein released was 75.5% at pH ~ 6.8 within 48 h with 83.3% of EE. The viability of Caco-2 cells against CTNP/B.b-sup was 90.3%. The effects of CTNP/B.b-sup on the expression levels of various oncogenes reveal a significant decrease in the expression of β-Catenin, PI3K, TGF-α, Bcl2, TLR4, CEA, and TGF-β oncogenes by 0.96, 0.37, 0.03, 0.41, 0.88, 0.69, and 0.71-fold, respectively. CTNP/B.b-sup induced the most significant reduction in TGF-α oncogene expression, with a decrease of 0.03-fold. Conversely, the strongest induction was observed in the expression of Caspase9 suppressor, with a 73.4-fold increase.
conclusionIn the present study, the CTNP/B.b-sup was demonstrated to possess the capability of modulating genes associated with CRC progression, thereby highlighting its significant pro-apoptotic potential. It can be concluded that CTNP/B.b-sup is a suitable drug delivery system with anticancer properties, which can be regarded as a complementary therapeutic approach for the treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.